||

Connecting Communities, One Page at a Time.

health and lifestyle

Assam Medical College faces severe staff shortage, over 120 doctor posts remain vacant

The staffing gap has increased workloads across departments, with nurses attending to large numbers of patients and diagnostic services disrupted by equipment failures.

Tamil Nadu records sharp rise in dengue, swine flu cases ahead of monsoon

Chennai reported the highest number of dengue infections, while August saw a significant jump in both diseases, raising concerns over further transmission during the upcoming rainy season.

FSSAI seizes misbranded infant food in Bengaluru, initiates legal action against company

The regulator found serious compliance violations during inspections, with 3.7 metric tons of expired products ordered for destruction under court directions to prevent their re-entry.

Bihar to screen 6 crore people in statewide door-to-door healthcare drive

The Bihar government has launched a statewide campaign to screen around six crore people aged 30 and above, with teams visiting villages and households to detect and treat serious and non-communicable diseases.

West Bengal health department identifies five districts as most dengue-prone

The state health department has identified Kolkata, Howrah, North 24 Parganas, South 24 Parganas and Murshidabad as the most dengue-prone districts amid rising cases and unpredictable rainfall during the monsoon.

Maharashtra FDA cancels Cipla facility licences in Pune over Reactin Plus irregularities

The regulator cited unauthorized promotional claims, stock record discrepancies, inadequate storage facilities and failure to fully comply with its recall order for the prescription medicine.

Rasonque daraxonrasib pancreatic cancer drug approved by the US FDA after trial showed improved survival

The ‘Undruggable’ Target Finally Has a Drug: FDA Approves Pancreatic Cancer Pill That Nearly Doubles Survival

Rasonque, developed by Revolution Medicines, targets RAS-driven tumors and extended median survival to 13.2 months from 6.7 months in a 500-patient Phase 3 trial.